alanylglutamine: Clinical Trials

30 trials of alanylglutamine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 5 unknown, 4 terminated, 2 withdrawn. 11 Phase 3, 9 Phase 4, 6 Phase 2, 5 Not applicable, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 311Completed 6, Unknown 3, Withdrawn 2
Phase 49Completed 7, Terminated 2
Phase 26Completed 2, Terminated 2, Recruiting 1, Unknown 1
Not applicable5Completed 3, Unknown 2
Phase 12Completed 1, Terminated 1

Follow alanylglutamine: new trials by email Literature Review of alanylglutamine trials Research Report on alanylglutamine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Perioperative Supplementation With Immunonutrition and Its Impact on Surgical Outcome and Pain in Oral Cavity or Mandibular Tumours
Standard feeding, Omega 3 and dipeptiven - Immunonutrition, Surgical Outcome
Not applicableCompletedCairo University1762023-02-012024-04-02
Effect of IV Alanyl Glutamine on Healing of Pressure Ulcers in Critically Ill Patients
alanyl-glutamine - Pressure Ulcer
Not applicableUnknownAir Force Specialized Hospital, Cairo, Egypt2002022-04-012022-10-19
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
Alanyl-glutamine - Clostridioides Difficile Infection, Clostridium Difficile Infection
Phase 2RecruitingUniversity of Virginia2602021-06-012024-10-26
Glutamine Supplementation and Short-term Mortality in Covid-19
Standard enteral nutrition, Glutamine - Covid19
Phase 3CompletedAssiut University602021-05-302021-11-05
Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF
L-alanyl-L-glutamine dipeptide, Placebo - Coronary Artery Bypass, Cardiopulmonary Bypass
Phase 3CompletedNational Cardiovascular Center Harapan Kita Hospital Indonesia602021-01-012023-11-13
Glutamine Effects in Burn Patients
Dipeptiven, normal Saline - Drug Effect
Phase 2 / Phase 3UnknownMenoufia University602020-06-012021-12-01
Citrullinemia for the Prediction of Enteral Nutrition Tolerance Among Critically Ill Patients
N2-L-Alanyl-L-Glutamine (Substance) - Enteral Nutrition, Intensive Care Unit
Not applicableCompletedCentre Hospitalier Universitaire de Besancon732019-11-282025-01-16
Reduction of Occurence of Acute Kidney Injury (AKI) Through Administration of Glutamine
L-Alanyl/L-Glutamine, Placebo - Cardiac Surgery, Acute Kidney Injury
Phase 3CompletedUniversity Hospital Muenster642019-07-182020-05-21
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection
Alanyl-glutamine - Clostridium Difficile Infection
Phase 2TerminatedUniversity of Virginia72015-04-012022-06-07
A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy Adhesions
L-Alanyl/L-Glutamine, Physiologic saline - Pelvic Adhesions
Phase 1 / Phase 2CompletedTemple Therapeutics BV472015-02-152021-05-07
Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation.
Enteral nutrition alanyl-glutamin, Dipeptiven - Myeloablative Allo-SCT
Phase 3UnknownUniversity Hospital, Clermont-Ferrand2402013-11-012016-07-29
Intervention and Mechanisms of Alanyl-Glutamine for Inflammation, Nutrition, and Enteropathy
Alanyl-Glutamine - Malnutrition, Environmental Enteropathy
Phase 3CompletedChildren's Hospital Medical Center, Cincinnati1122013-10-012016-08-01
Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery
Glutamine, Ringer's solution - Rheumatic Heart Disease, Coronary Heart Disease
Phase 2CompletedYuejiang Liu332013-01-012014-05-28
Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass
N(2)-L-Alanine L-Glutamine dipeptide, Placebo - Coronary Artery Disease
Phase 3CompletedMeshalkin Research Institute of Pathology of Circulation242012-01-012013-11-01
Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis
Dipeptiven (Alanyl-glutamine-dipeptide) - End Stage Renal Disease
Phase 1 / Phase 2TerminatedChristoph Aufricht252011-04-012015-09-11
The Clinical Role of Intravenous Glutamine in Trauma Patients Receiving Enteral Nutrition
Dipeptiven, normal saline - Multiple Trauma, Critically Ill
Phase 3UnknownRoyal Brisbane and Women's Hospital882011-03-012012-05-24
Modulation of Systemic Inflammatory Response in Critically Ill Children After Glutamine Supplementation
solution of amino acids supplemented with glutamine, amino acids not supplemented with glutamine - Inflammatory Response, Multi-organ Failure
Phase 4CompletedHospital Sant Joan de Deu1012010-04-012013-09-06
Microbial Invasion During Parenteral Nutrition in Surgical Infants Receiving Glutamine
Isonitrogenous Vaminolact, Dipeptiven (L-glutamine- Lalanine) - Surgical Infants Requiring Total Parenteral Nutrition
Phase 4CompletedInstitute of Child Health602009-07-012022-01-25
Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients
Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb), glutamine, oral diet enriched with arginine (Cubitan) - Gastric Cancer
Not applicableUnknownMedical University of Bialystok2402007-03-012020-03-17
Nutrition for Colorectal Cancer Patients and Neutrophil Functions
Standard (Kabiven), Standard-Glutamine, Standard-Omega 3 fatty acid - Malnutrition, Colorectal Cancer
Phase 4CompletedKocaeli University362007-01-012013-04-15

Showing 20 of 30. Sign in to see all of them.

Conditions studied

Critical Illness (5)  ·  Malnutrition (5)  ·  Diarrhea (4)  ·  Hyperphagia (3)  ·  Clostridium Infections (2)  ·  Coronary Artery Disease (2)  ·  Multiple Organ Failure (2)  ·  Stomach Neoplasms (2)  ·  Acute Kidney Injury (1)  ·  Brain Injuries, Traumatic (1)  ·  COVID-19 (1)  ·  Colorectal Neoplasms (1)  ·  Coma (1)  ·  Coronary Disease (1)  ·  Enterocolitis, Pseudomembranous (1)

Sponsors

University of Virginia (4)  ·  Jagiellonian University (2)  ·  Air Force Specialized Hospital, Cairo, Egypt (1)  ·  Assiut University (1)  ·  Cairo University (1)  ·  Centre Hospitalier Universitaire de Besancon (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Christoph Aufricht (1)  ·  Daren K. Heyland (1)  ·  Emory University (1)  ·  Hospital Sant Joan de Deu (1)  ·  Institute of Child Health (1)  ·  Kocaeli University (1)  ·  Medical University of Bialystok (1)  ·  Menoufia University (1)

Countries

Egypt (4)  ·  United States (4)  ·  France (3)  ·  Poland (3)  ·  Germany (2)  ·  Switzerland (2)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  China (1)  ·  Indonesia (1)  ·  Russia (1)  ·  Slovenia (1)

Top investigators

Aldo Lima, MD, PhD (1)  ·  Alexander Zarbock, MD, PhD (1)  ·  Anne Mercier, MD (1)  ·  Christoph Aufricht, Univ.Prof.Dr. (1)  ·  Cirle A. Warren, M.D. (1)  ·  Daren Heyland, MD (1)  ·  Donna Chizen, MD, FRCSC (1)  ·  Enas Mogawer, Professor (1)  ·  I Made Adi Parmana (1)  ·  Iolanda Jordan, PhMD (1)  ·  Jan Wernerman, MD, PhD (1)  ·  Jasna Uranjek, MD (1)  ·  Jeffrey Lipman, MBBCh, MD (1)

Results publications

PMID 18650630, PMID 21820770, PMID 22102646, PMID 23594003, PMID 24363760, PMID 24803474, PMID 24992948, PMID 25872934, PMID 26501700, PMID 31502272, PMID 32826717, PMID 36730070, PMID 37474181

NIH funding

2018 (1), U01DK069322 (1)